MedTrace Logo

Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition

NCT06409585 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 290

Last updated 2025-08-19

No results posted yet for this study

Summary

Heart scarring, also known as fibrosis, plays a major role in a lot of heart muscle abnormalities. These abnormalities of the heart muscle can lead to major issues such as symptoms of heart failure, dangerous heart rhythm disturbances and even death. However, a lot of these conditions are still not fully understood and treatment options are limited. We here aim to use a new radioactive dye called 68Ga-FAPI to identify patterns and the activity of heart muscle scarring. This radioactive dye is being used in humans particularly in identifying and monitoring cancers and has shown promise in identifying scarring in the heart as well. This will help us not only understand the underlying disease process and risk stratify these patients but also potentially help us develop new targeted therapies that can affect heart muscle scarring. Participants will undergo a baseline MRI scan using this new dye and a plain MRI scan will repeated 12-18 months after to see if there are any changes in the process.

Conditions

Interventions

DIAGNOSTIC_TEST

68Ga-FAPI or 18F-AlF-FAPI cardiac PET-MR

200MBq of the above named radiotracer will be administered for PET-MR

DIAGNOSTIC_TEST

Echocardiogram

Echocardiogram at baseline and 1 year follow-up

DIAGNOSTIC_TEST

Cardiac MRI

Cardiac MRI at 1 year

Sponsors & Collaborators

  • University of Edinburgh

    lead OTHER

Eligibility

Min Age
30 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2027-08-01
Completion
2028-01-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06409585 on ClinicalTrials.gov